-
公开(公告)号:US20180334495A1
公开(公告)日:2018-11-22
申请号:US15844391
申请日:2017-12-15
Applicant: GENENTECH, INC.
Inventor: Sek Chung FUNG , Zhengbin YAO
IPC: C07K16/18 , C12N15/113 , A61K45/06 , A61K38/17 , A61K39/395 , A61K38/00 , A61K39/00
CPC classification number: C07K16/18 , A61K38/00 , A61K38/1709 , A61K39/395 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2300/00 , C12N15/113
Abstract: The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic M retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5b, C6, C7, C8, C9, or C5b-9.